Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-2022
- Development stage
- Phase 1
- Lead developer
- Suzhou Suncadia Biopharmaceutical
- Administration
- Intravenous
01
Overview
SHR-2022 is an investigational drug currently in Phase 1 clinical trials for the treatment of advanced malignant tumors (neoplasms). It is administered as an intravenous injection, either alone or in combination with other anti-cancer therapies. The primary aim of ongoing studies is to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced or metastatic cancers. The drug is being developed by Shanghai Hengrui Pharmaceutical and Suzhou Suncadia Biopharmaceuticals. Its precise mechanism of action and molecular modality have not been publicly disclosed as of now[1][2].
- Other names
- SHR-2022 InjectionSHR2022 InjectionSHR 2022 Injection
Beyond the preview
Go deeper on SHR-2022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-2022.